These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 19264253)
21. Nitroprusside in critically ill patients with aortic stenosis. Karthikeyan G N Engl J Med; 2003 Aug; 349(8):811-3; author reply 811-3. PubMed ID: 12931715 [No Abstract] [Full Text] [Related]
22. [Vasodilator treatment of chronic heart failure]. Froer KL; Hall D; Goppel L; Rudolph W Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1117-9. PubMed ID: 1029939 [No Abstract] [Full Text] [Related]
23. [Vasodilator agents in the treatment of cardiac insufficiency]. Bertel O Ther Umsch; 1984 Feb; 41(2):117-24. PubMed ID: 6424258 [No Abstract] [Full Text] [Related]
24. Haemodynamic effects of intravenous quinaprilat in comparison to sodium nitroprusside in patients with chronic heart failure. Kieback AG; Grohmann A; Baumann G; Felix SB Int J Cardiol; 2007 Sep; 121(1):102-4. PubMed ID: 17098309 [TBL] [Abstract][Full Text] [Related]
25. [Pharmacology of vasodilator drugs; recent developments]. van Zwieten PA; van Meel JC; de Jonge A; Kalkman HO; Timmermans PB Verh Dtsch Ges Herz Kreislaufforsch; 1982; 48():78-86. PubMed ID: 7187165 [No Abstract] [Full Text] [Related]
26. Recent advances in vasodilator therapy. Part I: physiologic correlations. Aranda JM; Linares E; Hernández-López E; Cintrón G; Song S Bol Asoc Med P R; 1981 Jan; 73(1):3-10. PubMed ID: 7020713 [No Abstract] [Full Text] [Related]
27. [Changes of cardiac inside diameter and ejection fraction in patients with heart failure after the treatment with nitroprusside]. Qian ZX; Sun M; Chen YM Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):183-4. PubMed ID: 12575360 [No Abstract] [Full Text] [Related]
28. The role of vasodilating agents in the treatment of chronic heart failure. Gunnar RM Angiology; 1980 Aug; 31(8):526-32. PubMed ID: 7001960 [No Abstract] [Full Text] [Related]
29. [The role of vasodilator agents in the emergency treatment of heart failure]. You K Zhonghua Nei Ke Za Zhi; 1983 Feb; 22(2):111-4. PubMed ID: 6409536 [No Abstract] [Full Text] [Related]
35. [Administration of nitroprusside in the therapy of refractory cardiac failure (author's transl)]. Nikolić V; Sjerobabski V; Barić L; Pilas V; Planinc D; Vukosavić D Lijec Vjesn; 1981 Nov; 103(11):495-500. PubMed ID: 7343794 [No Abstract] [Full Text] [Related]
36. Aortic stenosis: from pressure overload to heart failure. Carabello BA Heart Fail Clin; 2006 Oct; 2(4):435-42. PubMed ID: 17448430 [No Abstract] [Full Text] [Related]
37. [Vasodilator therapy of congestive heart failure: comparison of hemodynamic effects after administration of nitroprusside i.v. and oral prazosin (author's transl)]. Mauri F; Gronda E; Bossi M; Rovelli F G Ital Cardiol; 1980; 10(4):414-23. PubMed ID: 7439582 [No Abstract] [Full Text] [Related]
38. Vasodilator agents in chronic heart failure. Chatterjee K Dan Med Bull; 1983 Apr; 30 Suppl 1():1-9. PubMed ID: 6345096 [No Abstract] [Full Text] [Related]
39. [Hemodynamic indices of patients with acute left-ventricular failure being treated with sodium nitroprusside]. Tatishvili NI; Chkhaidze ZK; Kurashvili RB; Mamatsashvili MD; Narsiia NN Ter Arkh; 1984; 56(4):112-5. PubMed ID: 6729714 [No Abstract] [Full Text] [Related]
40. [Clinical experiences and value of vasodilation in myocardial insufficiency]. Just H Verh Dtsch Ges Herz Kreislaufforsch; 1982; 48():87-97. PubMed ID: 7187166 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]